

Anti-BTLA/CD272 Antibody (Tifcemalimab)

Introduction

Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuator) monoclonal antibody. Tifcemalimab binds to BTLA, blocking the HVEM-BTLA interaction and thus blocking the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in cancer research.

Product parameters

Alternative Names	TAB-004, JS-004
Target Accession	Q7Z6A9
Target	BTLA / CD272
CAS number	2236068-83-8
Molecular Weight	146 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80 °C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

